- Recce has been recognized by the UK Government Innovation Agency as one of the most promising organizations for the UK AMR Inward Mission 2024.
- Recce selected as one of 18 organizations worldwide for its potential to tackle the global health threat of AMR and superbugs
- Professor Dame Sally Davies, former Chief Medical Officer for England, hosts a reception with selected organizations providing strategic partnership opportunities for Recce in the AMR field
SYDNEY, Australia, April 9, 2024 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), which is developing a new class of synthetic anti-infective drugs, today announced that The Agency for Innovation (Innovate UK) will take part in the prestigious UK Antimicrobial Resistance (AMR) Inward Mission 2024. At this event, scheduled to take place from June 2nd to 7th, 2024, our company will be featured as one. Promising organizations around the world are being recognized for their potential to fight AMR.
James Graham, CEO of Lecce Pharmaceuticals, said: “We are excited about the opportunity to work with the UK's leading AMR experts and institutions and appreciate the support of the UK Government.” “We believe this mission will catalyze our continued growth and success in developing potentially life-saving antimicrobial treatments.”
Through Innovate UK's rigorous selection process, Recce was selected from a large and competitive pool of international candidates (Australia, Canada, France, India, Italy, Netherlands, Nigeria, Norway, Switzerland, USA). It was recognized as one of 18 organizations in the world, highlighting its innovative points. approach and potential synergies with his AMR industry leaders in the UK;
UK AMR Inward Mission 2024 will feature a comprehensive program of partnership sessions, visits to world-class AMR infrastructure and interactions with key opinion leaders. Highlights of the event included a reception in Cambridge with Professor Dame Sally Davies, former UK Chief Medical Officer who served as Chief Medical Adviser to the UK Government and professional lead for all local authority public health officers. is.
The selection of Recce for the UK AMR Inward Mission represents a significant geographical opportunity for its global strategy, particularly in establishing a foothold in the UK's vibrant AMR research and development ecosystem. This work has allowed Recce to forge important partnerships, gain insight into regulatory pathways, and develop new markets, ultimately enabling him to innovate on the pressing global health challenge of AMR. This allows us to advance our mission of providing innovative solutions.
About Innovation UK
Innovate UK is the UK's national innovation agency. We support business-led innovation across every sector, technology and region in the UK. We help businesses grow through the development and commercialization of new products, processes and services, supported by a leading innovation ecosystem that is agile, comprehensive and easy to navigate.
About Lecce Pharmaceuticals Co., Ltd.
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) develops a new class of synthetic anti-infective drugs designed to address urgent global health challenges posed by antibiotic-resistant superbugs and emerging viral pathogens doing.
Recce's anti-infective drug pipeline includes three patented broad-spectrum synthetic polymer anti-infective drugs.® 327 is being developed as an intravenous and topical therapy for the treatment of serious and potentially life-threatening infections caused by Gram-positive and Gram-negative bacteria, including superbug types.Trial run® 435 as an orally administered therapy for bacterial infections. and RECCE® 529 for viral infections. Through its multilayered mechanism of action, Recce's anti-infective drug has the potential to overcome hypercellular mutation in bacteria and viruses, a challenge for all existing antibiotics to date.
FDA awarded RECCE® 327 Qualified Infectious Disease Product Designation under the Generating Antibiotic Initiatives Now (GAIN) Act – Labeled with Fast Track designation, which provides 10 years of market exclusivity following approval. In addition to this specification, RECCE® 327 is included in the Pew Charitable Trusts' global novel antibiotic development pipeline as the world's only synthetic polymer and sepsis treatment candidate in development.Trial run® 327 has not yet been approved for use on the market for human use, and further clinical trials are required to fully evaluate its safety and efficacy.
Recce fully owns automated manufacturing to support ongoing clinical trials. Recce's anti-infective pipeline aims to leverage the unique capabilities of its technologies to target synergistic unmet medical needs.
Corporate contact
james graham
Lecce Pharmaceuticals Co., Ltd.
+61 (02) 9256 2571
james.graham@recce.com.au
Media and Investor Relations (AU)
Andrew Geddes
City PR
+61 (02) 9267 4511
agedes@citypublicrelations.com.au
Media (USA)
Michael Fitzhugh
Lifecy Communications
mfitzhugh@lifescicomms.com
Investor Information (US and EU)
Girame Fun Rental Game
Life science advisor
gvanrenterghem@lifesciadvisors.com
